Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFB200301 (TNFR2 agonist) in advanced solid tumors
NCT05238883Phase 1Active, not recruiting
- Sponsor
- HiFiBiO Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of emunkitug in gastric cancer (GC), renal cell carcinoma (RCC), melanoma and 6 more (4 arms), sponsored by HiFiBiO Therapeutics. Primary endpoints: Adverse Events at 3 years and Recommended Phase 2 Dose at 3 years. Started Mar 2022; status: active, not recruiting.
02
Drugs
emunkitug
03
Conditions
gastric cancer (GC)renal cell carcinoma (RCC)melanomasarcomaTesticular Germ Cell Tumor (TGCT)
Beyond the preview
Go deeper on NCT05238883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238883.